natgillin/translations-raw huggingface dataset:
Common: swelling of the hands or legs 
Pogosti: otekanje dlani ali nog
• medicines which increase urine production (diuretics) 
• zdravila, ki povečajo nastajanje urina (diuretiki);
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any subsequent updates of the RMP. 
Imetnik dovoljenja za promet z zdravilom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih posodobitvah RMP.
- if you have type 1 diabetes. 
- če imate sladkorno bolezen tipa 1.
After an oral dose, the non-absorbed fraction recovered in faeces was 20-30 %. 
Po peroralnem odmerku je odkrit neabsorbiran delež v blatu znašal 20 do 30 %.
If you stop taking Ristfor, your blood sugar may rise again. 
Če prenehate jemati zdravilo Ristfor, se vam krvni sladkor lahko ponovno poviša.
• Your doctor may need to increase your dose to control your blood sugar. 
• Zdravnik vam bo za nadzor krvnega sladkorja morda moral povečati odmerek.
This medicine alone is unlikely to cause abnormally low blood sugar (hypoglycaemia). 
Malo verjetno je, da bi to zdravilo povzročilo nenormalno nizek krvni sladkor (hipoglikemijo).
Do not use this medicine after the expiry date which is stated on the blister and the carton after 'EXP'. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu in škatli poleg oznake "EXP".
A limited amount of data suggests the use of metformin in pregnant women is not associated with an increased risk of congenital malformations. 
Maloštevilni podatki nakazujejo, da uporaba metformina pri nosečnicah ni povezana s povečanim tveganjem za prirojene malformacije.
When this happens, sugar (glucose) builds up in the blood. 
Takrat se sladkor (glukoza) kopiči v krvi.
• metformin belongs to a class of medicines called biguanides. 
• Metformin spada v skupino zdravil, imenovanih bigvanidi.
Long-term treatment with metformin has been associated with a decrease in vitamin B12 absorption which may very rarely result in clinically significant vitamin B12 deficiency (e.g., megaloblastic anaemia). 
Dolgotrajno zdravljenje z metforminom je bilo povezano z zmanjšanjem absorpcije vitamina B12, kar lahko zelo redko povzroči klinično pomembno pomanjkanje vitamina B12 (npr. megaloblastno anemijo).
• with meals to lower your chance of an upset stomach. 
• skupaj s hrano, da se zmanjša možnost želodčnih težav.
Metformin increases the transport capacity of specific types of membrane glucose transporters (GLUT-1 and GLUT-4). 
Metformin povečuje transportno zmožnost specifičnih tipov membranskih prenašalcev za glukozo (GLUT-1 in GLUT-4).
Effects of other medicinal products on sitagliptin 
Učinki drugih zdravil na sitagliptin
These medical conditions can increase your chance of getting pancreatitis (see section 4). 
Ta zdravstvena stanja lahko povečajo možnost za nastanek pankreatitisa (glejte poglavje 4).
Adults with normal renal function (GFR ≥ 90 mL/min) 
Odrasli z normalnim delovanjem ledvic (GFR ≥ 90 ml/min)
• If you have reduced kidney function, your doctor may prescribe a lower dose. 
• Če imate zmanjšano delovanje ledvic, vam bo morda zdravnik predpisal manjši odmerek.
Component of a multi-pack, can't be sold separately. 
Del multi pakiranja, ni za posamično prodajo.
The prospective randomised (UKPDS) study has established the long-term benefit of intensive blood glucose control in type 2 diabetes. 
V prospektivni randomizirani študiji (UKPDS) so ugotovili dolgoročno korist intenzivne urejenosti glukoze v krvi pri sladkorni bolezni tipa 2.
The European Medicines Agency has waived the obligation to submit the results of studies with Ristfor in all subsets of the paediatric population in type 2 diabetes mellitus (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Ristfor za vse podskupine pediatrične populacije za sladkorno bolezen tipa 2 (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
This medicine can be used alone or with certain other medicines for diabetes (insulin, sulphonylureas, or glitazones). 
To zdravilo se lahko uporablja samostojno ali skupaj z določenimi drugimi zdravili za sladkorno bolezen (insulinom, sulfonilsečninami ali glitazoni).
Along with diet and exercise, this medicine helps lower your blood sugar. 
Skupaj z dieto in s telesno aktivnostjo vam to zdravilo pomaga znižati sladkor v krvi.
Opaque blisters (PVC/PE/PVDC and aluminum). 
Neprosojni pretisni omoti (PVC/PE/PVDC in aluminij).
Ristfor must be discontinued at the time of surgery under general, spinal or epidural anaesthesia. 
Uporabo zdravila Ristfor je treba v času kirurškega posega pod splošno, spinalno ali epiduralno anestezijo prekiniti.
Monitoring of renal function is necessary to aid in prevention of metformin-associated lactic acidosis, particularly in the elderly (see sections 4.3 and 4.4). 
Spremljanje delovanja ledvic je potrebno za preprečevanje laktacidoze, povezane z metforminom, zlasti pri starejših (glejte poglavji 4.3 in 4.4).
What you need to know before you take Ristfor 
Kaj morate vedeti, preden boste vzeli zdravilo Ristfor
Ristfor should not be used in patients with type 1 diabetes and must not be used for the treatment of diabetic ketoacidosis. 
Zdravila Ristfor se ne sme uporabljati pri bolnikih s sladkorno boleznijo tipa 1 in za zdravljenje diabetične ketoacidoze.
When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells. 
Kadar je koncentracija glukoze v krvi normalna ali zvišana, GLP-1 in GIP povečata sintezo insulina in njegovo sproščanje iz celic beta trebušne slinavke.
During treatment with Ristfor, your doctor will check your kidney function at least once a year or more frequently if you are elderly and/or if you have worsening kidney function. 
Med zdravljenjem z zdravilom Ristfor bo zdravnik vsaj enkrat letno preveril delovanje ledvic, če pa ste starejša oseba in/ali se vam delovanje ledvic slabša, pa še pogosteje.
STOP taking Ristfor and contact a doctor immediately if you notice any of the following serious side effects: 
Zdravilo Ristfor takoj PRENEHAJTE jemati in se posvetujte z zdravnikom, če opazite katerega koli od naslednjih resnih neželenih učinkov:
It is assumed that the pharmacokinetics of metformin absorption is non-linear. 
Predvidevamo, da je farmakokinetika absorpcije metformina nelinearna.
The patient should be informed and more frequent blood glucose monitoring performed, especially at the beginning of treatment with such medicinal products. 
Bolnika je treba s tem seznaniti in pogosteje opravljati teste za določanje koncentracije glukoze v krvi, še zlasti na začetku zdravljenja s takimi zdravili.
It is not known if sitagliptin is dialysable by peritoneal dialysis. 
Ni znano, ali se sitagliptin dializira s peritonealno dializo.
When blood glucose levels are low, insulin release is not enhanced and glucagon secretion is not suppressed. 
Kadar so ravni glukoze v krvi nizke, se izločanje insulina ne spodbudi in sekrecija glukagona se ne zavira.
• specific medicines for the treatment of bronchial asthma (β-sympathomimetics) 
• določena zdravila za zdravljenje bronhialne astme (β-simpatomimetiki);
In vitro and clinical data described below suggest that the risk for clinically meaningful interactions following co-administration of other medicinal products is low. 
Spodaj opisani podatki in vitro in klinični podatki kažejo, da je tveganje za klinično pomembne interakcije pri sočasni uporabi drugih zdravil majhno.
Hypoglycaemia has been reported in combination with sulphonylurea (13.8%) and insulin (10.9%). 
O hipoglikemiji so poročali pri kombinaciji s sulfonilsečnino (13,8 %) in z insulinom (10,9 %).
Among these patients, adverse events reported regardless of causal relationship to medicinal product occurring in at least 5 % included upper respiratory tract infection and nasopharyngitis. 
Pri teh bolnikih so neželeni učinki, o katerih so poročali ne glede na vzročno povezavo z zdravilom in ki so se pojavili pri vsaj 5 % bolnikov, vključevali okužbo zgornjih dihal in nazofaringitis.
In the event of an overdose, it is reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring (including obtaining an electrocardiogram), and institute supportive therapy if required. 
V primeru prevelikega odmerjanja so smiselni običajni podporni ukrepi, na primer odstranitev neabsorbiranega zdravila iz prebavil, uvedba kliničnega nadzora (vključno s spremljanjem elektrokardiograma) in po potrebi uvedba podpornega zdravljenja.
In clinical studies, approximately 13.5 % of the dose was removed over a 3- to 4-hour haemodialysis session. 
V kliničnih študijah so približno 13,5 % odmerka odstranili s 3- do 4-urno hemodializo.
The mean Vd ranged between 63 - 276 L. 
Povprečna vrednost volumna porazdelitve (Vd) je od 63 do 276 litrov.
The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. 
Inkretini so del endogenega sistema za fiziološko uravnavanje homeostaze glukoze.
• certain medicines used to treat stomach problems such as cimetidine 
• določena zdravila za zdravljenje trebušnih težav, kot je cimetidin;
Animal studies with metformin do not indicate harmful effects with respect to pregnancy, embryonic or foetal development, parturition or postnatal development (see also section 5.3). 
Študije na živalih z metforminom ne kažejo na škodljive vplive na nosečnost, razvoj zarodka/plodu, porod ali postnatalni razvoj (glejte tudi poglavje 5.3).
The blood peak is lower than the plasma peak and appears at approximately the same time. 
Največja koncentracija v krvi je manjša od največje koncentracije v plazmi, pojavi pa se približno ob istem času.
It is not known whether sitagliptin is excreted in human milk. 
Ni znano, ali se sitagliptin izloča v materino mleko.
Gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite occur most frequently during initiation of therapy and resolve spontaneously in most cases. 
Gastrointestinalni simptomi, kot so navzea, bruhanje, diareja, bolečina v trebuhu in izguba apetita, se pojavijo najpogosteje med začetkom zdravljenja in v večini primerov spontano izzvenijo.
This medicine helps to increase the levels of insulin produced after a meal and lowers the amount of sugar made by your body. 
To zdravilo pomaga povečati količino insulina, ki nastane po obroku, in zmanjšuje nastajanje sladkorja v telesu.
Elimination of sitagliptin occurs primarily via renal excretion and involves active tubular secretion. 
Izločanje sitagliptina poteka primarno prek ledvične sekrecije in vključuje aktivno tubularno sekrecijo.
It does not stimulate insulin secretion and therefore does not produce hypoglycaemia. 
Ne stimulira sekrecije insulina, zato ne povzroča hipoglikemije.
If acidosis of either form occurs, treatment must be stopped immediately and other appropriate corrective measures initiated. 
Če se pojavi acidoza v kateri koli obliki, je treba zdravljenje takoj prekiniti in primerno ukrepati.
The difference was mainly due to a higher percentage of patients in the placebo group experiencing 3 or more episodes of hypoglycaemia (9.1 vs. 19.8 %). 
Razlika je bila v glavnem zaradi večjega odstotka bolnikov, ki so doživeli 3 ali več epizod hipoglikemije v skupini, ki je prejemala placebo (9,1 proti 19,8 %).
Your doctor may ask you to stop Ristfor. 
Zdravnik vam bo morda naročil, da prenehate z jemanjem zdravila Ristfor.
• dolutegravir, a medicine used to treat HIV infection 
• dolutegravir, zdravilo za zdravljenje okužbe z virusom HIV;
What Ristfor is and what it is used for 
Kaj je zdravilo Ristfor in za kaj ga uporabljamo
These reactions include anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. 
Med temi reakcijami so anafilaksa, angioedem in eksfoliativna stanja na koži, vključno s Stevens-Johnsonovim sindromom.
Metformin is excreted in human milk in small amounts. 
Metformin se v majhnih količinah izloča v materino mleko.
• vandetanib, a medicine used to treat a specific type of thyroid cancer (medullary thyroid cancer) 
• vandetanib, zdravilo za zdravljenje določene vrste raka ščitnice (medularni rak ščitnice);
Ristfor contains two different medicines called sitagliptin and metformin. 
Zdravilo Ristfor vsebuje dve različni učinkovini, imenovani sitagliptin in metformin.
• iodinated contrast agents or alcohol-containing medicines 
• jodirana kontrastna sredstva ali zdravila, ki vsebujejo alkohol;
The dose of antihyperglycaemic therapy with Ristfor should be individualised on the basis of the patient's current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin. 
Odmerek zdravila Ristfor pri antidiabetičnem zdravljenju je treba prilagoditi na podlagi bolnikovega trenutnega režima zdravljenja, učinkovitosti in tolerabilnosti, pri tem pa se ne sme preseči največjega dovoljenega dnevnega odmerka 100 mg sitagliptina.
Pharmacotherapeutic group: Drugs used in diabetes, Combinations of oral blood glucose lowering drugs, ATC code: A10BD07 
Farmakoterapevtska skupina: Zdravila za zdravljenje diabetesa, Kombinacije peroralnih antidiabetikov, oznaka ATC: A10BD07
Sitagliptin is a potent and highly selective inhibitor of the enzyme DPP-4 and does not inhibit the closely-related enzymes DPP-8 or DPP-9 at therapeutic concentrations. 
Sitagliptin je močan in zelo selektiven zaviralec encima DPP-4 ter pri terapevtskih koncentracijah ne zavira sorodnih encimov DPP-8 ali DPP-9.
Packs of 14, 28, 56, 60, 112, 168, 180, 196 film-coated tablets, multi-packs containing 196 (2 packs of 98) and 168 (2 packs of 84) film-coated tablets. 
Pakiranja po 14, 28, 56, 60, 112, 168, 180, 196 filmsko obloženih tablet, multi pakiranja po 196 (2 pakiranji po 98) in 168 (2 pakiranji po 84) filmsko obloženih tablet.
Hospitalization for unstable angina 
Sprejem v bolnišnico zaradi nestabilne angine pektoris
The mean glipizide dose used in the comparator group was 10 mg per day with approximately 40 % of patients requiring a glipizide dose of  5 mg/day throughout the study. 
Povprečni odmerek glipizida, ki so ga uporabili v primerjalni skupini, je bil 10 mg na dan, pri čemer je ves čas trajanja študije približno 40 % bolnikov potrebovalo odmerek glipizida  5 mg/dan.
• medicines (taken by mouth, inhalation, or injection) used to treat diseases that involve inflammation, like asthma and arthritis (corticosteroids) 
• zdravila (zaužita, inhalirana ali injicirana) za bolezni, ki jih spremljajo vnetja, kot sta astma in artritis (kortikosteroidi);
No dose adjustment is necessary based on gender, race, or body mass index (BMI). 
Na podlagi spola, rase ali indeksa telesne mase (ITM) odmerka ni treba prilagoditi.
Improvements in surrogate markers of beta cell function, including HOMA-β (Homeostasis Model Assessment-β), proinsulin to insulin ratio, and measures of beta cell responsiveness from the frequently-sampled meal tolerance test were observed. 
Opazili so izboljšanje surogatnih markerjev funkcije celic beta, vključno s HOMA-β (Homeostasis Model Assessment-β), razmerjem proinsulin/insulin in meritvami odzivnosti celic beta pri tolerančnem testu s hrano (s pogostim vzorčenjem).
Sitagliptin is a substrate for human organic anion transporter-3 (hOAT-3), which may be involved in the renal elimination of sitagliptin. 
Sitagliptin je substrat za humani organski anionski prenašalec-3 (hOAT-3 - human organic anion transporter-3), ki bi bil lahko vključen v izločanje sitagliptina skozi ledvice.
Ristfor may cause a very rare, but very serious side effect called lactic acidosis, particularly if your kidneys are not working properly. 
Zdravilo Ristfor lahko povzroči zelo redek, a zelo resen neželeni učinek, imenovan laktacidoza, zlasti če ledvice ne delujejo pravilno.
This has been shown at therapeutic doses in controlled, medium-term or long-term clinical studies: metformin reduces total cholesterol, LDLc and triglyceride levels. 
Slednje so pokazali v kontroliranih, srednje dolgih ali dolgotrajnejših kliničnih študijah z uporabo terapevtskih odmerkov: metformin znižuje celokupni holesterol, LDL-holesterol in trigliceride.
If a patient wishes to become pregnant or if a pregnancy occurs, treatment should be discontinued and the patient switched to insulin treatment as soon as possible. 
Če želi bolnica zanositi ali če zanosi, je treba zdravljenje prekiniti, bolnica pa mora čim prej preiti na zdravljenje z insulinom.
In vitro data showed that sitagliptin is not an inhibitor of CYP isoenzymes CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 or 2B6, and is not an inducer of CYP3A4 and CYP1A2. 
In vitro pridobljeni podatki kažejo, da sitagliptin ni zaviralec izoencimov CYP CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 ali 2B6 in ni induktor CYP3A4 ter CYP1A2.
In controlled clinical trials, maximum metformin plasma levels (Cmax) did not exceed 5 µg/mL, even at maximum doses. 
V nadzorovanih kliničnih preskušanjih največja koncentracija metformina v plazmi (Cmax) tudi pri največjih odmerkih ni presegla 5 μg/ml.
The clinical relevance of this decrease is unknown. 
Klinični pomen tega ni znan.
Avoid excessive alcohol intake while taking Ristfor since this may increase the risk of lactic acidosis (see section “Warnings and precautions”). 
Med jemanjem zdravila Ristfor ne uživajte čezmernih količin alkohola, saj lahko to poveča tveganje za laktacidozo (glejte poglavje "Opozorila in previdnostni ukrepi").
In studies performed with the individual active substances, both sitagliptin and metformin are excreted in the milk of lactating rats. 
V študijah, opravljenih s posameznima učinkovinama, sta se sitagliptin in metformin izločala v mleko doječih podgan.
Metabolism may play a more significant role in the elimination of sitagliptin in the setting of severe renal impairment or end-stage renal disease (ESRD). 
Presnova ima lahko pomembnejšo vlogo pri izločanju sitagliptina pri hudi ledvični okvari ali pri končni ledvični odpovedi (ESRD - End-Stage Renal Disease).
Diagnostic laboratory findings are decreased blood pH (< 7.35), increased plasma lactate levels (> 5 mmol/L) and an increased anion gap and lactate/pyruvate ratio. 
Diagnostični laboratorijski izvidi so zmanjšan pH krvi (< 7,35), zvišane ravni laktata v plazmi (> 5 mmol/l) in zvečana anionska vrzel ter razmerje laktat/piruvat.
Evaluation should include serum electrolytes and ketones, blood glucose and, if indicated, blood pH, lactate, pyruvate, and metformin levels. 
Pregled mora vključevati kontrolo elektrolitov in ketonov v serumu, glukoze v krvi in, če je indicirano, vrednost pH v krvi ter raven laktata, piruvata in metformina.
These symptoms may happen when you start taking metformin and usually go away Common: a metallic taste 
Ti simptomi se lahko pojavijo na začetku jemanja metformina in običajno izginejo.
In case of dehydration (severe vomiting, diarrhoea, fever or reduced fluid intake), metformin should be temporarily discontinued and contact with a health care professional is recommended. 
V primeru dehidracije (hudo bruhanje, driska, zvišana telesna temperatura ali zmanjšan vnos tekočine) je treba jemanje metformina začasno prekiniti; priporoča se posvet z zdravstvenim delavcem.
For adult patients with type 2 diabetes mellitus: 
Za odrasle bolnike s sladkorno boleznijo tipa 2:
Ristfor may cause a very rare (may affect up to 1 in 10,000 people), but very serious side effect called lactic acidosis (see section “Warnings and precautions”). 
Zdravilo Ristfor lahko povzroči zelo redek (pojavi se lahko pri največ 1 od 10.000 bolnikov), a zelo resen neželeni učinek, imenovan laktacidoza (glejte poglavje "Opozorila in previdnostni ukrepi").
Sitagliptin is secreted in considerable amounts into the milk of lactating rats (milk/plasma ratio: 4:1). 
Pri doječih podganah se je sitagliptin v znatnih količinah izločal v mleko (razmerje mleko/plazma 4 : 1).
Renal clearance of metformin is > 400 mL/min, indicating that metformin is eliminated by glomerular filtration and tubular secretion. 
Ledvični očistek metformina je > 400 ml/min ter kaže, da se metformin izloča z glomerularno filtracijo in tubularno sekrecijo.
However, when driving or using machines, it should be taken into account that dizziness and somnolence have been reported with sitagliptin. 
Vendar pa je treba pri vožnji in upravljanju strojev upoštevati, da so pri uporabi sitagliptina poročali o omotici in zaspanosti.
A large overdose of metformin (or co-existing risks of lactic acidosis) may lead to lactic acidosis which is a medical emergency and must be treated in hospital. 
Precej preveliko odmerjanje metformina (ali sočasno tveganje za laktacidozo) lahko povzroči laktacidozo, ki pa je nujni primer in se mora zdraviti v bolnišnici.
• ranolazine, a medicine used to treat angina 
• ranolazin, zdravilo za zdravljenje angine pektoris;
The effects of potent CYP3A4 inhibitors in the setting of renal impairment have not been assessed in a clinical study. 
Učinkov močnih zaviralcev encima CYP3A4 pri ledvični okvari v klinični študiji niso ovrednotili.
Very common (may affect more than 1 in 10 people): low blood sugar Common: constipation 
Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov): nizek krvni sladkor Pogosti: zaprtje
Type 2 diabetes is a condition in which your body does not make enough insulin, and the insulin that your body produces does not work as well as it should. 
Sladkorna bolezen tipa 2 je bolezen, pri kateri v telesu ne nastaja dovolj insulina, delovanje nastalega insulina pa ni ustrezno.
Pharmacokinetic drug interaction studies with Ristfor have not been performed; however, such studies have been conducted with the individual active substances, sitagliptin and metformin. 
Študije farmakokinetičnih interakcij z zdravilom Ristfor niso bile izvedene, vendar pa so take študije opravili s posameznima učinkovinama, sitagliptinom in metforminom.
In 16-week studies in which dogs were treated with either metformin alone or a combination of metformin and sitagliptin, no additional toxicity was observed from the combination. 
V 16-tedenskih študijah, v katerih so psom dajali metformin sam ali v kombinaciji s sitagliptinom, zaradi kombinacije niso opazili nobenih dodatnih škodljivih učinkov.
You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dosage of Ristfor. 
Morda boste morali pogosteje opravljati preiskave glukoze v krvi in delovanja ledvic, zdravnik pa bo morda moral prilagoditi odmerek zdravila Ristfor.
Adverse reactions are listed below as MedDRA preferred term by system organ class and absolute frequency (Table 1). 
Neželeni učinki so navedeni spodaj in v skladu z MedDRA razvrščeni po organskih sistemih in absolutni pogostnosti (preglednica 1).
Hospitalization for heart failure 
Sprejem v bolnišnico zaradi srčnega popuščanja
Ristfor should be given twice daily with meals to reduce the gastrointestinal adverse reactions associated with metformin. 
Zdravilo Ristfor je treba jemati dvakrat na dan s hrano, da se zmanjšajo neželeni učinki metformina na prebavila.
If you forget to take Ristfor 
Če ste pozabili vzeti zdravilo Ristfor
Glucocorticoids (given by systemic and local routes) beta-2-agonists, and diuretics have intrinsic hyperglycaemic activity. 
Glukokortikoidi (dani sistemsko ali lokalno), beta-2-agonisti in diuretiki imajo intrinzično hiperglikemično aktivnost.
Prolonged haemodialysis may be considered if clinically appropriate. 
Pretehtati je treba možnost daljše hemodialize, če je klinično primerno.
Some adverse reactions were observed more frequently in studies of combination use of sitagliptin and metformin with other anti-diabetic medicinal products than in studies of sitagliptin and metformin alone. 
Nekatere neželene učinke so opazili pogosteje v študijah kombinirane uporabe sitagliptina in metformina z drugimi zdravili za zdravljenje sladkorne bolezni kot v študijah samo sitagliptina in metformina.